EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schoen, F.J.
Right arrow Articles by Levy, R.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schoen, F.J.
Right arrow Articles by Levy, R.J.

Eur J Cardiothorac Surg 2006;6:S91-S94
© 2006 Elsevier Science NL

Heart valve bioprostheses: antimineralization

F.J. Schoen 1 , 3 , R.J. Levy 2

a Department of Pathology, Brigham and Women's Hospital, Boston, Mass., USA
b Harvard Medical School, Boston, Mass., USA
c Department of Pediatrics and Communicable Diseases, University of Michigan Medical Center, Ann Arbor, Mich., USA

Clinical and experimental studies indicate that calcification of bioprosthetic valves depends on host, implant, and biomechanical factors. The earliest mineral deposits in both clinical and experimental bioprosthetic tissue are localized to transplanted connective tissue cells; collagen involvement occurs later. Passive calcium entry occurs unimpeded in cells modified by aldehyde cross-linking, but the mechanisms for calcium removal are dysfunctional; calcium influx contributes to apatite formation by reacting with compartmentalized, bound phosphorus. Specific strategies for prevention of bioprosthetic tissue mineralization involve modification of either valve preparation details or the local implant environment. Efficacy, mechanisms and safety must be demonstrated for any antimineralization strategy.

Key Words: Prosthetic valve mineralization • Antimineralization strategies




This article has been cited by other articles:


Home page
 CirculationHome page
E. Rieder, G. Seebacher, M.-T. Kasimir, E. Eichmair, B. Winter, B. Dekan, E. Wolner, P. Simon, and G. Weigel
Tissue Engineering of Heart Valves: Decellularized Porcine and Human Valve Scaffolds Differ Importantly in Residual Potential to Attract Monocytic Cells
Circulation, May 31, 2005; 111(21): 2792 - 2797.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1992 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.